Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation

Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio

October 12, 2023 12:27 AM UTC

The European Parliament’s Committee on the Environment, Public Health and Food Safety has posted a draft report with amendments to a European Commission proposal for the first major overhaul of European pharmaceutical law in 20 years, and amendments to an associated directive. Debate on the amendments could start next week.

Shares of dialysis providers sank Wednesday after Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said the Phase III FLOW kidney outcomes study of Ozempic semaglutide met criteria for an early stop due to efficacy. FLOW compared the once-weekly injectable drug with placebo in patients with Type II diabetes and chronic kidney disease. Novo gained 6% in New York, while shares of DaVita Inc. (NYSE:DVA) were off 17% and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) lost 18%...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article